Quant Healthcare Fund - Regular Plan Growth - Growth
Quant Money Managers Limited
₹17.44 (+0.91%)
NAV as of 9 Oct 2026
Minimum Investment: ₹5,000
Return
12.53% Returns for 1Y
Expense ratio & Others
- Net expense ratio
- 2.40%
- Exit load
- 0%
- Lock-in
- No
- Minimum investment
- ₹5,000
- Category
- Sector - Healthcare
Expense ratio is inclusive of GST. Returns may be taxed based on the fund type and your holding period — please read the scheme-related documents and consult a tax advisor. Figures are historical and do not guarantee future results.
Fund Returns Estimator
One-time investment
₹1,000
6 months
₹1,165
Invested ₹1,000
▲+16.51%1 year
₹1,125
Invested ₹1,000
▲+12.53%3 years
₹1,182
Invested ₹1,000
▲+18.23%
Based on the fund’s historic trailing returns — a planning illustration, not a guarantee of future results.
Invest One-TimePlan it your way
The figures above are fixed to this fund’s past returns over set periods. Use a calculator to set your own amount, tenure and expected rate of return.
Risk level
Riskometer scale
- Low
- Low to Moderate
- Moderate
- Moderate to High
- High
- Very HighThis fund
Riskometer level assigned by the fund house as per SEBI norms. It can change as the scheme’s portfolio changes.
Fund benchmark
| Primary Index Name | BSE Healthcare PR INR |
|---|---|
| Secondary Index Name | BSE Healthcare PR |
| Index Name | Nifty Healthcare TR INR |
| Weighting | 100% |
Returns
| 1Y | 3Y | 5Y | 10Y | |
|---|---|---|---|---|
| Fund returns (%) | +12.53% | +18.23% | — | — |
| Cumulative returns (%) | +12.53% | +65.27% | — | — |
Fund Manager
| Manager | Yug Tibrewal |
|---|---|
| Role | Manager |
| Manager Tenure | 1.57 yrs |
About Fund
| Date of Incorporation | 18 Jul 2023 |
|---|---|
| Fund House | Quant Money Managers Limited |
| Custodian | HDFC Bank Ltd |
| Registrar / Transfer Agent | Quant Money Managers Limited |
| Address | HDFC Bank House,Kamala Mills Compound,Senapati Bapat Marg,,Lower Parel (W), |
Top Holdings
| Company | Weightage (%) |
|---|---|
| GlaxoSmithKline Pharmaceuticals Ltd | 10.58% |
| Cipla Ltd | 10.01% |
| Zydus Wellness Ltd | 9.33% |
| Zydus Lifesciences Ltd | 9.30% |
| Aster DM Quality Care Ltd Ordinary Shares | 9.25% |
| RPG Life Sciences Ltd | 8.88% |
| Pfizer Ltd | 8.83% |
| Glenmark Pharmaceuticals Ltd | 8.70% |
| Anthem Biosciences Ltd | 8.66% |
| Viyash Scientific Ltd | 8.62% |
| Alivus Life Sciences Ltd | 8.08% |
| HFCL Ltd | 7.89% |
| Concord Biotech Ltd | 7.03% |
| Zydus Wellness Ltd | 6.75% |
| SMS Pharmaceuticals Ltd | 6.71% |
| Ipca Laboratories Ltd | 6.22% |
| Adani Enterprises Ltd | 5.64% |
| Aurobindo Pharma Ltd | 5.15% |
| Biocon Ltd | 4.89% |
| ICICI Bank Ltd | 4.79% |
| ICICI Prudential Life Insurance Co Ltd | 4.35% |
| HDFC Life Insurance Co Ltd | 4.12% |
Investment Strategy
The primary investment objective of the scheme is to provide capital appreciation by investing in equity and equity related instruments including derivatives and debt and money market instruments. However, there can be no assurance that the investment objective of the Scheme will be realized, as actual market movements may be at variance with anticipated trends.
Capital appreciation over long term
Mutual fund investments are subject to market risks. Read all scheme-related documents carefully. The data shown is for information only and does not constitute investment advice.